What moved in a tumour type this month, who is running it, and which targets have the genetics behind them.

High-risk and relapsed disease: MYCN amplification, ALK mutations and anti-GD2 therapy.

WNT, SHH, Group 3 and Group 4 disease, and relapse after craniospinal radiotherapy.

H3 K27-altered tumours of the brainstem and midline, with no curative treatment: ONC201 and cell therapy trials.

Posterior fossa group A and ZFTA-fusion tumours, where surgery and radiotherapy remain the only standard.

A SMARCB1-deficient brain tumour of infants and young children: EZH2 inhibition and intensive chemotherapy.

Relapsed and refractory disease after frontline cure rates: blinatumomab, inotuzumab and CD19 CAR-T cells.

An EWSR1 fusion-driven sarcoma of children and young adults; relapsed disease has few options.

The commonest bone cancer in teenagers; relapsed and metastatic disease remain hard to treat.

The commonest soft-tissue sarcoma of childhood; PAX3::FOXO1 fusion-positive and metastatic disease do worst.

IDH-wildtype disease that almost always recurs: EGFR, the blood-brain barrier and cell therapy attempts.

IDH-mutant astrocytoma and oligodendroglioma, IDH inhibitors, and BRAF- and H3-altered tumours.

EGFR, ALK, KRAS G12C and the ADC wave in first and later lines.

HR+/HER2-, HER2-low and TNBC: CDK4/6, oral SERDs, PI3K pathway and TROP2 ADCs.

RAS(ON) inhibitors, pan-KRAS and the long wait for a second-line standard.

MSI-H immunotherapy, BRAF V600E, HER2 and KRAS G12C combinations.

Menin inhibitors, FLT3 and IDH combinations, venetoclax backbones and what comes after.

Asciminib and the STAMP inhibitors, treatment-free remission and resistance after ponatinib.

BCMA and GPRC5D CAR-T cells and bispecifics, and what is left after triple-class exposure.